menu search

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...

November 3, 2023, 11:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Bausch health (bhc) q3 earnings & sales beat, '23 view updated

Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth....

November 3, 2023, 3:47 pm

Plains all american reports third-quarter 2023 results & raises 2023 guidance

Announces Capital Allocation Updates & Permian Bolt-On Acquisitions HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Na...

November 3, 2023, 11:30 am

Currys agrees sale of greek business

Currys PLC (LSE:CURY) has announced it has agreed terms for the sale of its Greek and Cypriot wing Kotsovolos for €200 million (£175 million). Kots...

November 3, 2023, 3:38 am

Pacira (pcrx) q3 earnings and revenues miss, '23 view updated

Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales....

November 2, 2023, 2:17 pm

Fca unveils fresh guidance amidst crypto marketing turmoil in the uk

The Financial Conduct Authority (FCA) has updated its guidance for cryptoasset firms, following recent ...

November 2, 2023, 1:31 pm

In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting

New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies;...

November 2, 2023, 1:17 pm

Exelixis (exel) q3 earnings and sales miss, annual view updated

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance....

November 2, 2023, 12:47 pm

Autolus therapeutics reports third quarter 2023 financial results and business updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biolog...

November 2, 2023, 11:11 am

Hydrogen utopia hails ohrid medical cannabis certification

Hydrogen Utopia International PLC (LSE:HUI, OTCQB:HUIPF) has updated that Ohrid Organics Ltd, in which ...

November 2, 2023, 5:36 am

Smartrent: heading in the right direction

Today, we take an updated look at SmartRent, Inc., a company that offers building hardware and cloud-ba...

November 1, 2023, 2:43 pm

Fca issues warning against saxo bank impersonators

The UK Financial Conduct Authority (FCA) has raised a red flag against fraudulent entities mimicking multi-asset investment firm Saxo Bank. These impo...

November 1, 2023, 1:44 pm

Electric royalties highlights promising developments across royalty portfolio

Electric Royalties Ltd (TSX-V:ELEC, OTC:ELECF) has updated investors on recent promising developments a...

November 1, 2023, 9:32 am

Leggett & platt: the 7.7% dividend may not be worth it after the poor q3

Leggett & Platt's Q3 results showed a decline in revenue and EPS due to weak demand for their products, particularly in the Bedding and Furniture segm...

November 1, 2023, 4:36 am

New position statement supports permanent standard time

American Academy of Sleep Medicine says U.S. should eliminate daylight saving time DARIEN, Ill., Oct. 31, 2023 (GLOBE NEWSWIRE) — An...

October 31, 2023, 8:41 pm


Search within

Pages Search Results: